Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.
Mixed lymphohematopoietic chimerism can be induced in mice with bone marrow transplantation (BMT) after a nonmyeloablative preparative regimen that includes cyclophosphamide, anti-T-cell antibody therapy, and thymic irradiation. These mixed chimeras are resistant to the induction of graft-versus-host disease (GVHD) after delayed donor leukocyte infusions (DLIs), despite a potent lymphohematopoietic graft-versus-host reaction that converts the mixed chimeric state to a full donor one. Based on this animal model, we initiated a trial of nonmyeloablative therapy with HLA-matched or -mismatched donor BMT and DLI for refractory hematologic malignancies. Twenty-one of 36 patients enrolled in this trial received a genotypically (n = 20) or phenotypically (n = 1) HLA-matched donor transplant; results reported here are for those patients only. Preparative therapy consisted of cyclophosphamide in doses of 150 to 200 mg/kg; peritransplant antithymocyte globulin; thymic irradiation (in patients who had not received previous mediastinal radiation therapy); and cyclosporine. Eighteen of 20 evaluable patients developed persistent mixed lymphohematopoietic chimerism as defined by >1% donor peripheral white blood cells until at least day 35 posttransplantation. Ten patients received prophylactic DLI beginning 5 to 6 weeks after BMT for conversion of mixed chimerism to full donor hematopoiesis and to optimize a graft-versus-leukemia effect. Fourteen of 20 evaluable patients (70%) achieved an antitumor response; 8 of these responses were complete, and 6 were partial. Of the 8 evaluable patients who received prophylactic DLI, 6 showed conversion to full donor chimerism. Five of the 9 evaluable patients (56%) who received prophylactic DLI achieved a complete response, compared with 3 of 11 patients (27%) who did not receive prophylactic DLI. Currently 11 patients are alive, and 7 of these are free of disease progression at a median follow-up time of 445 days (range, 105-548 days) posttransplantation. Transplantation-related complications included cyclophosphamide-induced cardiac toxicity in 3 of 21 patients (14%) and grade II or greater GVHD in 6 patients (29%). One patient (5%) died from a complication of BMT, and 1 patient (5%) died from GVHD after 2 prophylactic DLIs were given for conversion of chimerism. In summary, mixed lymphohematopoietic chimerism was reproducibly induced after a novel nonmyeloablative preparative regimen incorporating chemotherapy, peritransplant antithymocyte globulin, and thymic irradiation, allowing for early administration of DLI in 10 of 21 patients. After treatment, striking antitumor responses were observed in the majority of patients with chemotherapy-refractory hematologic malignancies.
Spitzer
T R
TR
Bone Marrow Transplantation Program/Department of Medicine, Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, 02114, USA.
McAfee
S
S
Sackstein
R
R
Colby
C
C
Toh
H C
HC
Multani
P
P
Saidman
S
S
Weyouth
D W
DW
Preffer
F
F
Poliquin
C
C
Foley
A
A
Cox
B
B
Andrews
D
D
Sachs
D H
DH
Sykes
M
M
D000328:Adult; D000818:Animals; D000961:Antilymphocyte Serum; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000473:pathology*; D002470:Cell Survival; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000009:adverse effects; D016572:Cyclosporine; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D005500:Follow-Up Studies; D005838:Genotype; D006082:Graft Enhancement, Immunologic; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000209:etiology / Q000401:mortality; D020544:Graft vs Leukemia Effect; D006680:HLA Antigens / Q000032:analysis; D006331:Heart Diseases / Q000139:chemically induced; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D006648:Histocompatibility; D006801:Humans; D017708:Leukocyte Transfusion / Q000009:adverse effects; D008297:Male; D051379:Mice; D008875:Middle Aged; D023421:Models, Animal; D010641:Phenotype; D012074:Remission Induction; D015203:Reproducibility of Results; D016879:Salvage Therapy; D016019:Survival Analysis; D013601:T-Lymphocytes / Q000276:immunology; D013950:Thymus Gland / Q000528:radiation effects; D019172:Transplantation Conditioning / Q000009:adverse effects; D014184:Transplantation, Homologous / Q000009:adverse effects / Q000473:pathology*; D016896:Treatment Outcome
D000961:Antilymphocyte Serum; D006680:HLA Antigens; D016572:Cyclosporine; D003520:Cyclophosphamide